Novitium Pharma LLC is a pharmaceutical company founded in 2016 and headquartered in East Windsor, New Jersey. In November 2021, the formerly private company was acquired by ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) for a total potential consideration of up to $210 million and now operates as a subsidiary. The company has approximately 91 to 100 employees.
As an operating company, Novitium Pharma specializes in the development, manufacturing, and distribution of niche generic prescription pharmaceutical products. Its product portfolio spans a wide range of dosage forms, including tablets, capsules, oral solutions, gels, and powders. The company focuses on developing complex generics, Abbreviated New Drug Applications (ANDAs), and 505(b)(2) products, which are new formulations or uses of existing drugs. All of its manufacturing is based in its U.S. facility.
Novitium Pharma is an active operating company in the patent litigation landscape, a common posture for a generic drug manufacturer. The provided data shows one tracked case where the company is a plaintiff, filed in the Delaware District Court, a common venue for pharmaceutical patent litigation. This type of litigation is often related to the Hatch-Waxman Act, where generic manufacturers challenge the patents of branded drugs.
The most notable event for the company was its 2021 acquisition by ANI Pharmaceuticals. The deal was intended to significantly enhance ANI's research and development capabilities, particularly in the generic and 505(b)(2) sectors, and to add a U.S.-based manufacturing facility. The founders of Novitium joined the executive team of ANI as part of the acquisition.